Iopromide Injection

Product Description

Iopromide Injection

The presence of LOCM such as Uttravist in the blood stream encourages lowering of blood\viscosity v ia osmodilution. LOCM passes in to glomerular filtrate. Residual hyperosmolality of filtrate increases osmotic pressure of tubular fluid and reduces water reabsorption. More water is retained in tubules, d iluting and further lowering viscosity of tubular fluid (osmodiuresis-). Preserved GFR and fluid flow through tubules and renal blood vessels.

Key Traits

•     Pyrogen-Free aqueous solution
•     Helps diagnose problems with brain, heart, and blood vessels
•     Nonionic sterile, clear, colorless to slightly yellow
•     No preservatives

Preclinical evidence

Unlike IOCM, LOCM such as Ultravist encourages dilution of blood and urine, lowering in vivo viscosity and preserving renal hemodynamics.

Clinical evidence

Osmodilution and osmodiuresis has seen in patients receiving Ultravist': Marked (~20%) decrease in blood viscosity measure in 10 patients undergoingDSA with Ultravist' 370.

Clinical data

In humans undergoing cardiac intervention, compared to IOCM iodixanol, LOCM Ultravist